This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignees: Hirotsu Bio Science Inc., Honda Motor Ltd., Ltd.. Active years: 2025-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025-2026
Title: Masaki Mori: Innovator in Veterinary Cancer Diagnosis
Introduction
Masaki Mori is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of veterinary medicine, particularly in cancer diagnosis for pet animals. His innovative approach has the potential to improve the health and well-being of non-primate mammals.
Latest Patents
Masaki Mori holds a patent for a method of examining cancer in pet animals. This method involves evaluating the taxic behavior of nematodes toward a urine sample from a subject mammal. This innovative technique offers a new avenue for diagnosing cancer in non-primate mammals, which can lead to earlier detection and treatment.
Career Highlights
Mori is associated with Hirotsu Bio Science Inc., a company focused on advancing medical diagnostics. His work at the company has been instrumental in developing new methodologies for cancer detection in animals. With a patent portfolio that includes 1 patent, he continues to push the boundaries of veterinary science.
Collaborations
Masaki Mori collaborates with notable colleagues such as Takaaki Hirotsu and Satoru Kaifuchi. Their combined expertise fosters an environment of innovation and research, contributing to advancements in veterinary diagnostics.
Conclusion
Masaki Mori's contributions to veterinary medicine through his innovative patent demonstrate his commitment to improving animal health. His work has the potential to change the landscape of cancer diagnosis in pets, making a significant impact in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile